{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:53:54Z","timestamp":1780649634237,"version":"3.54.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective of this study is to report results from the open-label extension (OLE) of the OPTIMAL trial of oral octreotide capsules (OOC) in adults with acromegaly, evaluating the long-term durability of therapeutic response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The study design is an OLE of a double-blind placebo-controlled (DPC) trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients completing the 36-week DPC period on the study drug (OOC or placebo) or meeting predefined withdrawal criteria were eligible for OLE enrollment at 60 mg\/day OOC dose, with the option to titrate to 40 or 80 mg\/day. The OLE is ongoing; week 48 results are reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty patients were enrolled in the OLE, 20 each having received OOC or placebo, with 14 and 5 patients completing the DPC period as responders, respectively. Ninety percent of patients completing the DPC period on OOC and 70% of those completing on placebo completed 48 weeks of the OLE. Maintenance of response in the OLE (i.e. insulin-like growth factor I (IGF1) \u2264 1.0 \u00d7 upper limit of normal (ULN)) was achieved by 92.6% of patients who responded to OOC during the DPC period. Mean IGF1 levels were maintained between the end of the DPC period (0.91 \u00d7 ULN; 95% CI: 0.784, 1.045) and week 48 of the OLE (0.90 \u00d7 ULN; 95% CI: 0.750, 1.044) for those completing the DPC period on OOC. OOC safety was consistent with previous findings, with no increased adverse events (AEs) associated with the higher dose and improved gastrointestinal tolerability observed over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with acromegaly maintained long-term biochemical response while receiving OOC, with no new AEs observed with prolonged OOC exposure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1530\/eje-22-0220","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T15:33:46Z","timestamp":1664465626000},"page":"733-741","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":16,"title":["Durable biochemical response and safety with oral octreotide capsules in acromegaly"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-7093","authenticated-orcid":false,"given":"Susan L","family":"Samson","sequence":"first","affiliation":[{"name":"Department of Medicine and Neurological Surgery, Mayo Clinic , Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B","family":"Nachtigall","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Massachusetts General Hospital and Department of Medicine, Harvard Medical School , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[{"name":"Pituitary Center, Oregon Health & Sciences University , Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-8803","authenticated-orcid":false,"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[{"name":"University Medical Centre Ljubljana , Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J","family":"Manning","sequence":"additional","affiliation":[{"name":"Dunedin Hospital , Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanaska","family":"Elenkova","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Medical University Sofia, USHATE \u2018Acad. Ivan Penchev\u2019 , Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Molitch","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine , Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H","family":"Ludlam","sequence":"additional","affiliation":[{"name":"Amryt Pharmaceuticals , Dublin, Ireland"},{"name":"Recordati Rare Diseases , Lebanon, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Patou","sequence":"additional","affiliation":[{"name":"Amryt Pharmaceuticals , Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asi","family":"Haviv","sequence":"additional","affiliation":[{"name":"Amryt Pharmaceuticals , Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke R","family":"Biermasz","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[{"name":"Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J","family":"Strasburger","sequence":"additional","affiliation":[{"name":"Clinical Endocrinology, Charite-Universit\u00e4tsmedizin , Campus Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation , Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[{"name":"Pituitary Center, Cedars-Sinai Medical Center , Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"2023012409100165100_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nature Reviews Disease Primers"},{"key":"2023012409100165100_bib2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nature Reviews Endocrinology"},{"key":"2023012409100165100_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"2023012409100165100_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocrine Reviews"},{"key":"2023012409100165100_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"2023012409100165100_bib6","doi-asserted-by":"crossref","first-page":"101309","DOI":"10.1016\/j.beem.2019.101309","article-title":"The burden of disease for pituitary patients","volume":"33","author":"Biermasz","year":"2019","journal-title":"Best Practice and Research: Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/jim-2017-000570","article-title":"Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly","volume":"66","author":"Liu","year":"2018","journal-title":"Journal of Investigative Medicine"},{"key":"2023012409100165100_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"2023012409100165100_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4172\/clinical-practice.1000386","article-title":"Acromegaly: current therapies benefits and burdens","volume":"15","author":"Yedinak","year":"2018","journal-title":"Clinical Practice"},{"key":"2023012409100165100_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocrine Disorders"},{"key":"2023012409100165100_bib11","doi-asserted-by":"crossref","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Frontiers in Endocrinology"},{"key":"2023012409100165100_bib12","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib13","doi-asserted-by":"crossref","first-page":"105.e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"2023012409100165100_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nature Reviews Endocrinology"},{"key":"2023012409100165100_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","article-title":"High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial","volume":"161","author":"Giustina","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"2023012409100165100_bib17","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2017-00142","article-title":"High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study","volume":"102","author":"Giustina","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A pituitary society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"2023012409100165100_bib19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","article-title":"Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy","volume":"164","author":"Mazziotti","year":"2011","journal-title":"European Journal of Endocrinology"},{"key":"2023012409100165100_bib21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","article-title":"Current and emerging aspects of diabetes mellitus in acromegaly","volume":"27","author":"Frara","year":"2016","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"2023012409100165100_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2753.2007.00821.x","article-title":"Open label extension studies and patient selection biases","volume":"14","author":"Hemming","year":"2008","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"2023012409100165100_bib23","first-page":"3555","article-title":"International multicenter validation study of the SAGIT\u00ae instrument in acromegaly","volume":"106","author":"Giustina","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4158\/EP15913.RA","article-title":"Historical response rates of somatostatin analogues in the treatment of acromegaly: a systematic review","volume":"22","author":"Shanik","year":"2016","journal-title":"Endocrine Practice"},{"key":"2023012409100165100_bib25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib26","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib27","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023012409100165100_bib28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11102-021-01148-1","article-title":"COVID-19 and the pituitary","volume":"24","author":"Frara","year":"2021","journal-title":"Pituitary"},{"key":"2023012409100165100_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12020-020-02565-1","article-title":"Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era","volume":"71","author":"Giustina","year":"2021","journal-title":"Endocrine"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/187\/6\/EJE-22-0220.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/187\/6\/EJE-22-0220.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/6\/733\/48837727\/eje-22-0220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/6\/733\/48837727\/eje-22-0220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:18:01Z","timestamp":1676391481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/187\/6\/733\/6979892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eje-22-0220","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,10,26]]}}}